StockNews.com cut shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) from a buy rating to a hold rating in a report released on Thursday morning.
Separately, HC Wainwright dropped their target price on shares of TRACON Pharmaceuticals from $120.00 to $60.00 and set a buy rating for the company in a research report on Wednesday, April 3rd.
Read Our Latest Analysis on TRACON Pharmaceuticals
TRACON Pharmaceuticals Price Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.13). The firm had revenue of $0.10 million for the quarter. During the same quarter in the prior year, the company posted ($7.20) earnings per share. As a group, equities research analysts anticipate that TRACON Pharmaceuticals will post -4 EPS for the current year.
TRACON Pharmaceuticals Dividend Announcement
The company also recently disclosed a dividend, which will be paid on Monday, July 8th. Shareholders of record on Friday, June 28th will be given a $0.045 dividend. This represents a yield of 40.3%. The ex-dividend date is Thursday, June 27th.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Read More
- Five stocks we like better than TRACON Pharmaceuticals
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- Using the MarketBeat Stock Split Calculator
- MarketBeat Week in Review – 6/24 – 6/28
- How to buy stock: A step-by-step guide for beginners
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.